According to our results, we have successfully proven that AML cell lines (Figure 4) and patient-derived AML blasts (Figure 6) expressing either CD33, CD123 or both can be targeted via CD33 or CD123 simply by replacing the respective RevTM. This evidence concerns the gene CD33 and acute myeloid leukemia.